在EGFR-突变的高级NSCLC中使用阿米万塔马布-拉泽提尼布的整体存活率EGFR
James Chih-Hsin Yang1, Shun Lu2, Hidetoshi Hayashi3
1National Taiwan University Cancer Center, National Taiwan University Hospital, Taipei, Taiwan.
The New England journal of medicine
|September 9, 2025
概括
与奥西默提尼布相比,阿米万塔姆巴-拉泽提尼布显著改善了EGFR突变非小细胞肺癌患者的整体存活率. 然而,它与较高的严重不良事件发生率有关.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 临床试验 临床试验
背景情况:
- 此前,3期试验的结果显示,阿米万塔马布-拉泽提尼布的无进展生存期比奥西默提尼布在以前未经治疗的EGFR突变的先进非小细胞肺癌 (NSCLC) 中有所改善.
- 这项试验的最终整体生存分析正在等待.
研究的目的:
- 在之前未经治疗的EGFR突变高级NSCLC中,报告amivantamab-lazertinib与osimertinib的最终整体生存结果.
- 评估阿米万他马布-拉泽提尼布在这个患者群体中的安全性.
主要方法:
- 一项3期试验随机分配了429名先前未经治疗的EGFR突变高级NSCLC的参与者,接受阿米万塔-拉泽提尼布或奥西默提尼布.
- 总体存活率被评估为一个关键的二次终点,安全性也受到监测.
主要成果:
- 与奥西默提尼布相比,阿米万塔马布-拉泽尔提尼布的整体存活时间明显更长 (HR,0.75;P=0.005),3年存活率分别为60%和51%.
- 与奥西默提尼布 (52%) 相比,阿米万塔-拉泽尔提尼布 (80%) 观察到3级或更高的不良事件的发生率更高,主要是与皮肤有关的事件,静脉血栓塞栓症和输液反应.
- 随着延长的随访,没有出现新的安全信号.
结论:
- 与奥西默提尼布相比,阿米万塔姆巴-拉泽尔提尼布显著提高了以前未经治疗的EGFR突变高级NSCLC患者的整体存活率.
- 阿米万他马布-拉泽提尼布的改善生存益处伴随着严重不良事件的风险增加.
相关概念视频
01:21Cancer Survival Analysis
650
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
650
02:57Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
02:56Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
02:50Combination Therapies and Personalized Medicine
5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K